M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Short cationic lipopeptides as effective antibacterial agents: Design, physicochemical properties and biological evaluation
Fazren Azmi,Alysha G. Elliott,Nirmal Marasini,Soumya Ramu,Zyta M. Ziora,Angela M. Kavanagh,Mark A. T. Blaskovich,Mark E. Cooper,Mariusz Skwarczynski,Istvan Toth +9 more
TL;DR: These short lipopeptides are composed of cationic lysine and hydrophobic lipoamino acids that replicate the amphiphilic properties of natural antimicrobial peptides and have the potential to be developed as new antibacterial agents against drug-resistant Gram-positive bacteria.
Journal ArticleDOI
Glycation in diabetic nephropathy
TL;DR: It has become apparent that decreasing the accumulation of AGEs or interrupting their downstream effects on the kidney, are desirable therapeutic targets for the treatment of diabetic renal disease.
Journal ArticleDOI
Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies.
TL;DR: The histological nature of the increase in mesenteric arterial mass and the role of elevated ACE activity in diabetic vascular hypertrophy by administration of an ACE inhibitor (perindopril) provide new insights into the mechanisms of vascular complications of diabetes.
Journal ArticleDOI
Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Karin Jandeleit-Dahm,Markus Lassila,Belinda J Davis,Riccardo Candido,Colin I. Johnston,Terri J. Allen,Louise M Burrell,Mark E. Cooper +7 more
TL;DR: The results suggest that the anti-atherosclerotic effect conferred by omapatrilat treatment in the diabetic apo E-KO mouse is predominantly mediated by its capacity to inhibit local vascular ACE at the tissue level in the aorta and kidney.
Journal ArticleDOI
Antimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species.
Jessica L. Chitty,Mark S. Butler,Azzah Suboh,David Edwards,Mark E. Cooper,James A. Fraser,Avril A. B. Robertson +6 more
TL;DR: Testing synthetic octapeptin C4 derivatives provided insight into the structure activity relationships, revealing that the lipophilic amino acid moieties are more important to the activity than the cationic diaminobutyric acid groups.